These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 16800837

  • 1. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.
    Cooper A, Drake J, Brankin E, PERSIST Investigators.
    Int J Clin Pract; 2006 Aug; 60(8):896-905. PubMed ID: 16800837
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY.
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [Abstract] [Full Text] [Related]

  • 8. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG.
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [Abstract] [Full Text] [Related]

  • 9. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
    Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D.
    Curr Med Res Opin; 2005 Dec; 21(12):1895-903. PubMed ID: 16368038
    [Abstract] [Full Text] [Related]

  • 10. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M, Viapiana O, Gatti D, Adami S.
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [Abstract] [Full Text] [Related]

  • 11. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
    Binkley N, Martens MG, Silverman SL, Derman RJ, Greenwald M, Kohles JD, Bachmann GA.
    South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R.
    Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
    Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, Miller PD, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD.
    Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M, Xing XP, Zhang ZL, Liu JL, Zhang ZL, Liu DG, Xia WB, Meng XW.
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [Abstract] [Full Text] [Related]

  • 17. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
    Blumentals WA, Harris ST, Cole RE, Huang L, Silverman SL.
    Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
    [Abstract] [Full Text] [Related]

  • 18. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.
    Kastelan D, Lozo P, Stamenkovic D, Miskic B, Vlak T, Kolak Z, Milas Ahic J, Altabas V, Crncevic Orlic Z, Korsic M.
    Clin Rheumatol; 2009 Mar; 28(3):321-6. PubMed ID: 19031095
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
    Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD.
    Ann Rheum Dis; 2006 May; 65(5):654-61. PubMed ID: 16339289
    [Abstract] [Full Text] [Related]

  • 20. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
    Guañabens N, Monegal A, Cerdá D, Muxí Á, Gifre L, Peris P, Parés A.
    Hepatology; 2013 Dec; 58(6):2070-8. PubMed ID: 23686738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.